Related Experiment Video
Updated: Oct 11, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
A Meta-Analysis of Hypnotic Interventions for Depression Symptoms: High Hopes for Hypnosis?
Leonard S Milling1, Keara E Valentine1, Hannah S McCarley1
1University of Hartford.
Abstract:
This meta-analysis quantifies the effectiveness of hypnosis for treating the symptoms of depression. To be included in the meta-analysis, studies were required to use a between-subjects or mixed-model design in which a hypnotic intervention for depression was compared with a control condition in reducing depression symptoms. Of 197 records screened, 10 studies incorporating 13 trials of hypnosis met the inclusion criteria. The mean weighted effect size for 13 trials of hypnosis at the end of active treatment was 0.71 (p ≤ .001), indicating the average participant receiving hypnosis showed more improvement than about 76% of control participants. The mean weighted effect size for four trials of hypnosis at the longest follow-up was 0.52 (p ≤ .01), indicating the average participant treated with hypnosis showed more improvement than about 51% of control participants. These effect sizes are comparable to those associated with well-known psychological interventions for depression (e.g., Beck's cognitive therapy, interpersonal therapy) and suggest hypnosis is a very effective way of alleviating the symptoms of depression. Clinicians may wish to give serious consideration to hypnosis as a treatment option when working with clients and patients who are depressed.
Related Concept Videos
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antidepressant Drugs: MAOIs and Other Agents
Depressive Disorders: MDD and Dysthymia
Depression: Overview
The Placebo Effect

